Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock ...

Is Biogen (NASDAQ: BIIB) about to be acquired? One news article published on Wednesday reported that this is a possibility. As a result, the company's shares shot up almost 10% higher on the day. It ...

The past six months have been a windfall for Biogen’s shareholders. The company’s stock price has jumped 41.7%, setting a new ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated a ‘Neutral’ rating on the stock and raised the price target to $130 from ...

Biogen Inc's (NYSE: BIIB) short interest as a percent of float has fallen 32.24% since its last report. According to exchange reported data, there are now 4.47 million shares sold short, which is 3.93 ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the ...

Shares of Biogen BIIB gained 9.5% on Dec 29 following news on its potential acquisition by the South-Korean conglomerate Samsung Group. Per an article in The Korean Economic Daily, the U.S.-based ...

Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...